Tonix Pharmaceuticals expands its fibromyalgia drug TONMYA’s sales team and advances a Phase II trial with 3,300 participants.
Tonix Pharmaceuticals is scaling its TONMYA sales force to approximately 150 representatives by September, citing strong launch progress. The company reported growing sales, improved launch metrics, and enhanced patient access for the fibromyalgia treatment, the first of its kind for the condition.
The company also outlined plans for TNX-4800, a Phase II trial enrolling around 3,300 participants. Management highlighted TONMYA’s market potential, though no prior sales data or consensus estimates were provided for comparison.
No immediate market reaction was detailed in the source.